Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 10,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 10,000 shares of Akero Therapeutics stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $53.81, for a total transaction of $538,100.00. Following the completion of the transaction, the chief operating officer now directly owns 251,147 shares of the company’s stock, valued at $13,514,220.07. The trade was a 3.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jonathan Young also recently made the following trade(s):

• On Thursday, January 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $28.03, for a total transaction of $280,300.00.
• On Tuesday, December 10th, Jonathan Young sold 2,503 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total transaction of $77,067.37.
• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.13, for a total value of $321,300.00.

Akero Therapeutics Trading Up 2.0 %

NASDAQ AKRO opened at $57.56 on Thursday. Akero Therapeutics, Inc. has a 12 month low of $15.32 and a 12 month high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The firm’s 50-day moving average is $31.64 and its two-hundred day moving average is $29.48. The stock has a market capitalization of $4.02 billion, a P/E ratio of -15.35 and a beta of -0.11.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). On average, sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on AKRO shares. Canaccord Genuity Group increased their target price on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Citigroup increased their price target on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. HC Wainwright boosted their price target on shares of Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Finally, Morgan Stanley lifted their target price on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, Akero Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $75.86.

Institutional Trading of Akero Therapeutics

A number of large investors have recently modified their holdings of AKRO. Proficio Capital Partners LLC acquired a new position in Akero Therapeutics during the 4th quarter worth $320,000. Handelsbanken Fonder AB increased its position in shares of Akero Therapeutics by 5.0% in the 4th quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company’s stock valued at $584,000 after purchasing an additional 1,000 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Akero Therapeutics by 1.3% in the 4th quarter. Rhumbline Advisers now owns 105,686 shares of the company’s stock valued at $2,940,000 after purchasing an additional 1,310 shares in the last quarter. abrdn plc lifted its position in shares of Akero Therapeutics by 118.7% during the 4th quarter. abrdn plc now owns 269,782 shares of the company’s stock worth $7,505,000 after purchasing an additional 146,424 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Akero Therapeutics by 10.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company’s stock worth $412,000 after purchasing an additional 1,446 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.